SABCS 2021 Conference Coverage on VuMedi


 

SABCS 2021 Update on T-DXd vs.T-DM1 in High-Risk HER2+ Residual Invasive EBC Following Neoadjuvant Therapy: Phase 3 DESTINY-Breast05 Trial

503 views
December 16, 2021
Comments 0
Login to view comments. Click here to Login